ProShares S&P Kensho Cleantech ETF (ARCA: CTEX)

에 대한 최신 뉴스 ProShares S&P Kensho Cleantech ETF (ARCA:CTEX)

Technology

Industrials

Utilities

Other

Consumer Cyclical

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the Index. The Index selects companies focused on building the technologies or products that enable the generation of clean energy, such as solar, wind, geothermal, hydrogen, and hydroelectric. The Index includes companies focused on building technologies or products that enable generation of energy in a clean manner.

Sunnova Energy International Incorporation Com

Sunrun Inc

American Superconductor Corp

Altus Power Inc

Ge Vernova Inc

Arcosa Inc

Ormat Technologies Inc

Canadian Solar Inc

Nextracker Inc

Enphase Energy Inc Common Stock

Proshares S&P Kensho Cleantech ETF

Analyst Color

Equities

Large Cap

News

Price Target

Reiteration

Analyst Ratings

Movers

Trading Ideas

CNRG

CTEX

SEDG

솔라엣지 테크놀로지스(NASDAQ:SEDG) 주가는 화요일에 급등했다. 월요일(6일) 골드만삭스의 애널리스트 브라이언 리는 솔라엣지의 목표주가를 19달러에서 21달러로 상향 조정하고 매수 의견을 재확인했다.

골드만삭스 애널리스트: 솔라엣지, 구조조정으로 비용 절감하고 잉여현금흐름 상승 예상

ProShares S&P Kensho Cleantech ETF

Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) has outperformed the market over the past 5 years by 3.97% on an annualized basis producing an average annual return of 16.44%. Currently, Commercial Metals has a market capitalization of $5.41 billion. 
Buying $1000 In CMC: If an investor had bought $1000 of CMC stock 5 years ago, it would be worth $2,116.10 today based on a price of $47.57 for CMC at the time of writing.
<h3>Commercial Metals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736454634_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Commercial Metals Stock In The Last 5 Years

When you're approaching retirement, your net worth becomes a scoreboard. It reflects decades of hard work—saving, investing, paying off debts—and gives you a sense of where you stand. Are you sitting comfortably in the middle class, <a href="https://www.benzinga.com/personal-finance/24/05/39069576/are-you-rich-heres-the-net-worth-you-need-to-be-poor-middle-class-and-wealthy">firmly in the "rich" category</a> or struggling to make ends meet?
Net worth, the total value of your assets (like your home, retirement savings and investments) minus your debts (mortgages, loans, credit cards), offers a clearer picture of your financial health than income alone. Income can vary yearly, but your net worth reveals how well you've built and preserved your wealth over time.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
According to finance author Geoff Schmidt, who analyzed data from the Federal Reserve's latest Survey of Consumer Finances, retiree wealth can be grouped into key percentiles. Here's how he breaks it down in a 2023 YouTube video:
At the lower end of the scale, retirees in the bottom 20th percentile have a net worth of $10,000 or less. These individuals likely don't own property and rely heavily on Social Security or small pensions. It's a challenging position, as even covering basic expenses or handling unexpected costs can be a struggle.
The middle class&#8217;s 50th percentile has a net worth of about $281,000. This usually includes home equity, retirement savings and <a href="https://www.benzinga.com/24/12/42516732/the-average-401k-balance-soars-to-a-record-breaking-high-is-your-nest-egg-keeping-pace">a 401(k)</a>. It's a solid foundation, but retirees in this range still need to budget carefully to ensure their money lasts.
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Climbing higher, the 70th to 90th percentiles (upper-middle-class retirees) have net worths ranging from $201,800 to $608,900. These retirees enjoy more financial flexibility, often with diversified assets that provide a comfortable cushion for unexpected expenses or a more relaxed lifestyle.
Then, there are <a href="https://www.benzinga.com/personal-finance/24/06/39143700/are-you-richer-than-your-peers-the-net-worth-needed-to-be-in-the-top-10-of-your-age">the 90th percentile and above</a>—the rich retirees—start with a net worth of $1.9 million. At this level, retirees can afford luxuries like extensive travel, philanthropic efforts and legacy planning.
For the very wealthy, in the 95th percentile and beyond, net worth reaches $3.2 million or more. These retirees may own multiple properties, significant investments or even private businesses. And the rarest of the rare—the 99th percentile—boasts a staggering $16.7 million net worth. At this level, money is no longer a concern; it's a gateway to a lifestyle of total financial freedom.
However, wealth isn't just about the numbers. Context matters. For example, $1.9 million might go a long way in a small town but feel stretched in a high-cost urban area. Similarly, being debt-free can make a smaller net worth feel like a fortune, while heavy debt can weigh down even a significant nest egg.
Trending: <a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a>
For perspective, the Federal Reserve's broader data shows net worth benchmarks across all age groups:
• Poverty Class: $6,030
• Lower-Middle Class: $43,760
• Middle Class: $104,700
• Upper-Middle Class: $201,800
• Wealthy: $608,900
Most people's net worth peaks between the ages of 65 and 74, thanks to paid-off mortgages, maxed-out retirement savings and decades of compounding interest.
Wherever you land on the spectrum, your net worth isn't just a ranking; it's a tool to help you assess your financial health and plan for the future. Thoughtful planning can make all the difference in retirement, whether just getting by or living large.
If you're unsure how to make the most of your retirement savings or protect and grow your wealth, consider<a href="https://www.benzinga.com/money/are-you-rich"> consulting a financial advisor.</a> They can help you develop a strategy tailored to your needs so you can spend less time worrying about money and more time enjoying this next chapter of life.
Read Next:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

Does Your Net Worth Make You A Poor, Middle-Class Or Rich Retiree? Find Out Where Your Nest Egg Lands You

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 118.71% at $3.92</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 45.83% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 26.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 17.68% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 14.29% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 8.53% at $13.18</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 7.83% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 4.26% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 3.85% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 3.74% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 3.09% at $1.48</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 22.22% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 10.07% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed down 9.84% at $4.75</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 9.53% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 8.59% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 6.60% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 6.57% at $2.10</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 6.28% at $2.66</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 6.26% at $0.20</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 5.52% at $1.37</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 4.69% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 4.64% at $0.80</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 4.23% at $0.97</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 4.02% at $1.67</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 3.94% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 3.59% at $1.88</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 3.42% at $5.07</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BLOZF

BMMJ

CARA

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CWBHF

FFNTF

FUAPF

GRWG

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

NWVCF

OILFF

RSSFF

SNDL

SOLCF

TCNNF

TLRY

Cannabis Stock Movers For January 9, 2025

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ETFs delivered over 100% gains in 2024. That&#8217;s four times the returns of the S&amp;P 500 index. The Roundhill Magnificent Seven ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>), meanwhile, lagged at 65%, proving the tech elite can't always <a href="https://www.benzinga.com/crypto">keep up with crypto</a>.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), a reliable proxy for the S&amp;P 500, posted a respectable 24.4% gain over the past year. 
It has faltered recently, dropping 2.51% over the last month.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010925&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09133705/Screenshot-2025-01-10-at-12.06.12-AM.png" alt="" class="wp-image-726699" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09133705/Screenshot-2025-01-10-at-12.06.12-AM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09133705/Screenshot-2025-01-10-at-12.06.12-AM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010925&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
With the stock price below its eight-, 20- and 50-day simple moving averages, SPY's technical outlook remains strongly bearish.
That said, a glimmer of hope lies in its 200-day SMA (simple moving average), which signals a bullish undertone at $555.48 compared to SPY's current $589.49 price. Short-term pain may precede long-term gains, as buying pressure hints at future bullish movement.
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/12/42746036/is-spy-losing-its-spark-the-sp-500s-risk-conundrum">Is SPY Losing Its Spark? The S&amp;P 500&#8217;s Risk Conundrum</a>
<h2 class="wp-block-heading">Bitcoin ETFs Shine Despite Headwinds</h2>
The iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), a proxy of Bitcoin performance, crushed benchmarks with a 100.3% return in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010925&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09133725/Screenshot-2025-01-10-at-12.06.34-AM.png" alt="" class="wp-image-726700" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09133725/Screenshot-2025-01-10-at-12.06.34-AM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09133725/Screenshot-2025-01-10-at-12.06.34-AM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010925&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Despite a slight 2.54% dip last month, IBIT's long-term technicals remain robust, trading well above its 200-day SMA at $40.17. However, recent selling pressure and a price of $53.34 below its eight and 20-day SMAs indicate a short-term bearish trend.
With Bitcoin ETFs delivering unmatched growth, even slight headwinds haven't dampened their shine.
<h2 class="wp-block-heading">MAGS: Tech Titans In Neutral</h2>
The Roundhill Magnificent Seven ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>), a barometer for the magnificent seven tech giants, climbed 64.89% last year, a commendable performance but still lagging Bitcoin ETFs.
The MAGS ETF offers equal-weight exposure to the Magnificent Seven stocks:
<ul>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</li>
<li>Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).</li>
</ul>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010925&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09133743/Screenshot-2025-01-10-at-12.06.49-AM.png" alt="" class="wp-image-726701" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09133743/Screenshot-2025-01-10-at-12.06.49-AM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09133743/Screenshot-2025-01-10-at-12.06.49-AM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010925&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
MAGS has mostly stalled in recent months, with a 0.24% gain over the past month and signs of short-term selling pressure.
Its price of $55.04 sits below its eight and 20-day SMAs but above the 50 and 200-day SMAs, reflecting a mix of caution and resilience. As tech struggles to regain momentum, investors may seek opportunities elsewhere.
Crypto steals the spotlight as SPY and MAGS navigate choppy waters. Can Bitcoin ETFs keep their lead in 2025?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42895703/bitcoin-etfs-turn-one-90-gains-volatility-trump-era-hopes-for-2025">Bitcoin ETFs&#8217; First Year Delivers Massive Returns As 2025 Brings Questions</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Broad U.S. Equity ETFs

Specialty ETFs

Technicals

Tech

ETFs

$BTC

AAPL

AMZN

GOOG

GOOGL

IBIT

MAGS

MSFT

NVDA

TSLA

Bitcoin ETFs Quadruple SPY Returns, Magnificent 7 Plays Catch-Up

There has been more supply, or shares for sale, than there has been demand, or shares to buy, for ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>), <a href="https://www.benzinga.com/quote/ON/news" target="_blank" rel="noopener">push</a><a href="https://www.benzinga.com/quote/ON/news">ing the price lower.</a>
There is a good chance that a new downtrend is forming. This is why our team of technical analysts has made it our Stock of the Day.
Sometimes, analysts overcomplicate technical analysis. They seem to forget that if understood and applied correctly, it is the analysis of supply and demand in a market.
If demand and supply are equal, or if there&#8217;s more demand than supply, traders and investors who wish to sell can do so without any issues. But if there is more supply than there is demand, sellers will need to offer their shares out at a discount to get the interest of those who may wish to buy.
This will force the stock into a downtrend.
Read Also: <a href="https://www.benzinga.com/markets/eurozone/25/01/42900748/us-dollar-drops-on-report-of-trump-tariff-plan-shift">US Dollar Drops on Report of Trump Tariff Plan Shift</a>
Price levels that have more demand than supply are called support levels. Downtrends pause or end when they reach support levels.
As you can see on the chart, the $61 level has been support for ON Semiconductor. Downtrends ended at this level in October 2023 and April 2024.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="556" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart-1024x556.png" alt="" class="wp-image-726838" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart-1024x556.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart-768x417.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/09151205/On-chart.png 1489w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Sometimes stocks rally after they reach support. This happens when some of the buyers who created the support become concerned. They are worried that other traders and investors who wish to buy will increase the prices they are willing to pay for shares.
These concerned buyers know that the sellers will go to whoever is willing to pay the highest price. As a result, they increase the prices they are willing to pay. Other concerned buyers see this and do the same thing.
This could result in a bidding war or snowball effect that pushes the price higher. This is what happened the last two times ON reached $61.
However, this support level appears to have been broken, with shares closing below it.
This could mean the people who created the support with their buy orders have left the market. They have either canceled or finished their orders.
Sellers may be forced once again to push the price lower to get the attention of buyers. This could cause a new downtrend in <a href="https://www.benzinga.com/quote/ON">ON Semiconductor</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42896114/us-2025-recession-odds-plummet-good-news-or-warning-sign">US 2025 Recession Odds Plummet: Good News Or Warning Sign?</a></li>
</ul>
Photo: Shutterstock

Stock Of The Day: Will On Semiconductor's Meltdown Continue?

Kratos Defense &amp; Security's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NYSE">KTOS</a>) short percent of float has risen 3.0% since its last report. The company recently reported that it has 3.54 million shares sold short, which is 2.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kratos Defense &amp; Security Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736453720_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kratos Defense &amp; Security has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kratos Defense &amp; Security's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kratos Defense &amp; Security's peer group average for short interest as a percentage of float is 7.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

KTOS

Peering Into Kratos Defense & Security's Recent Short Interest

Alliant Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NYSE">LNT</a>) short percent of float has risen 9.49% since its last report. The company recently reported that it has 7.74 million shares sold short, which is 3.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alliant Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736453715_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alliant Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Alliant Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alliant Energy's peer group average for short interest as a percentage of float is 2.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Alliant Energy?

BOK Financial's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NYSE">BOKF</a>) short percent of float has risen 25.0% since its last report. The company recently reported that it has 293 thousand shares sold short, which is 1.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>BOK Financial Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736453710_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for BOK Financial has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing BOK Financial's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, BOK Financial's peer group average for short interest as a percentage of float is 3.70%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BOKF

How Is The Market Feeling About BOK Financial?

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 20 years by 6.3% on an annualized basis producing an average annual return of 14.61%. Currently, Chemed has a market capitalization of $7.97 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 20 years ago, it would be worth $15,287.93 today based on a price of $532.02 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736453707_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chemed Stock In The Last 20 Years

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) has outperformed the market over the past 5 years by 6.31% on an annualized basis producing an average annual return of 18.79%. Currently, Williams Companies has a market capitalization of $69.22 billion. 
Buying $1000 In WMB: If an investor had bought $1000 of WMB stock 5 years ago, it would be worth $2,371.32 today based on a price of $56.78 for WMB at the time of writing.
<h3>Williams Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736452810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Williams Companies 5 Years Ago Would Be Worth This Much Today

Electric vehicle company BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) is launching the first electric vehicle to come with a starting price under $30,000 in Australia, a move that could boost the country's <a href="https://www.benzinga.com/electric-vehicles">electric vehicle market.</a>
What Happened: Along with investing in blue-chip U.S. companies, Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) CEO Warren Buffett has recognized the investment opportunity<a href="https://www.benzinga.com/news/financing/24/12/42535041/warren-buffett-gains-exposure-to-digital-banks-in-africa-south-america-heres-how"> in emerging markets.</a>
One of Buffett's investments is owning a stake in Chinese company BYD, a global leader in electric vehicle. While Buffett has <a href="https://www.benzinga.com/markets/equities/24/06/39481191/warren-buffets-berkshire-drops-byd-stake-despite-ev-leader-seeing-record-sales">sold a portion</a> of the company's stake in BYD, Berkshire still owns around 4.9% of the company, representing around $1.8 billion in the Berkshire portfolio.
BYD could see a boost to its growth in 2025 thanks to the launch of a new version of its popular Dolphin EV in Australia.
A new stripped-down version of the Dolphin comes with a starting price of $29,900 in Australia, as <a href="https://electrek.co/2025/01/08/byd-just-launched-first-ev-priced-under-30000-australia/">reported </a>by Electrek, <a href="https://www.smh.com.au/politics/federal/chinese-giant-brings-first-ev-for-under-30-000-to-australia-20250108-p5l2vb.html">citing </a>The Sydney Morning Herald.
BYD has launched models like the Dolphin, Atto 3 and Seagull in Australia over the years and it now has the cheapest EV in the country, replacing the previous record of $30,990 by the MG4, which later raised its price to $38,000.
The lower-cost model does not include some normal Dolphin features like a sunroof, heated seats and a wireless phone charger. The new Dolphin model comes with the same battery range of 350 km (217 miles) as the other Dolphin models.
Deliveries of the new Dolphin model are set to begin in March.
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/25/01/42798998/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: BYD is one of the largest electric vehicle companies in the world, selling 4.27 million new energy vehicles globally, which includes electric vehicles and plug-in hybrids, in 2024. This total was up 41% year-over-year.
In Australia, BYD ranked second for 2024 EV sales and had a 14.6% year-over-year gain in units sold. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) ranked first in 2024 with a market share of 42% of EVs in Australia, but saw its year-over-year sales decline 16.8%, as <a href="https://www.drive.com.au/news/australias-best-selling-electric-cars-2024/">reported </a>by Drive.
Other EV companies like BYD saw their sales gain 28.8% year-over-year while Tesla fell, helping to set a record in Australia for a sixth straight year. The country had 91,292 EVs sold across cars, SUVs and light commercial vehicles, up 4.7% year-over-year and representing 7.4% of all new vehicles sold in the year.
EV sales faced pressure in Australia in the second half of 2024 with an overall drop of 6.9% year-over-year, with Tesla sales falling 25.8% year-over-year and other EV models gaining 9.6% year-over-year.
Tesla had the top two selling vehicles in Australia in 2024 with the Model Y and model 3 ranking first and second respectively.
BYD had three of the top 10 selling EVs in the country with the Seal, Atto 3 and Dolphin ranking fourth, fifth and eighth respectively.
A new lower-priced Dolphin could continue to cut into Tesla's market share. The EV company has watched its market share in Australia fall from 59% in 2022 to 53% in 2023 to 42% in 2024.
The Shark, which is BYD's first pickup truck, has over 5,500 preorders placed according to the report and deliveries begin soon. BYD will also launch the new Sealion 07, which is called a Model Y competitor. The Sealion 07 starts at under $60,000, falling in similar range of the Model Y, which starts at $55,900.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/25/01/42832123/warren-buffett-beats-sp-500-in-2024-how-oracle-of-omahas-returns-compare-over-past-20-years">Warren Buffett Beats S&amp;P 500 In 2024, How Oracle Of Omaha&#8217;s Returns Compare Over Past 20 Years</a></li>
</ul>
BYD photo

Management

BYDDF

BYDDY

Warren Buffett-Backed BYD Launches Australia's First EV Under $30K: How The Move Could Strengthen Fight Against Elon Musk's Tesla

Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares dipped 11.2% to $9.60 during Wednesday&#8217;s session, pulling back<a href="https://www.benzinga.com/topic/novavax"> following recent strength. </a>
Shares of vaccine makers are volatile this week after the first bird flu death was reported in the U.S. Additionally, a recent CDC <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">report</a> noted an increase in acute respiratory illness activity.
What To Know: As a company specializing in vaccine development, Novavax is positioned as a potential player in addressing such outbreaks, particularly given its history of <a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants">creating vaccines</a> for infectious diseases.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42897161/apples-24-year-70000-climb-since-itunes-faces-2025-test">Apple&#8217;s 24-Year 70,000% Climb Since iTunes Launch Faces 2025 Test</a>
While <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">traditional bird flu vaccines</a> from Sanofi, CSL Seqirus and GlaxoSmithKline are already stockpiled, they target older H5N1 strains, leaving potential room for innovation and updates.
Novavax, with its proprietary recombinant nanoparticle vaccine technology, could be seen as a contender to develop a next-generation bird flu vaccine if demand grows. The bird flu outbreak, which has <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42471357/egg-hyperinflation-could-spike-grocery-prices-why-cal-maine-vital-farms-are-soaring">devastated poultry farms</a> and raised concerns about viral mutations, could also underscore the need for advanced vaccine platforms.
Investor speculation about potential government funding or contracts to combat the outbreak could likely contribute to volatility in Novavax shares, despite the CDC stating that <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">public risk remains low</a>.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies</a>
<h2 class="wp-block-heading">How To Buy NVAX Stock</h2>
By now you're likely curious about how to participate in the market for Novavax &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Novavax, which is trading at $9.60 as of publishing time, $100 would buy you 10.41 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVAX has a 52-week high of $23.86 and a 52-week low of $3.53.
Image courtesy of <a href="https://pixabay.com/illustrations/ai-generated-stock-exchange-bull-8477673/">Pixabay</a>

Health Care

NVAX

Why Novavax Stock Is Volatile This Week

James Howells, who is infamously known for having accidentally thrown away a hard drive containing 8,000 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), has suffered a new setback in his quest to <a href="https://www.benzinga.com/markets/cryptocurrency/22/08/28706518/meet-a-man-on-a-quest-to-find-about-180-million-in-bitcoin-buried-in-a-landfill">reclaim his fortune</a>.
What Happened: A high court ruling by Judge Keyser KC has dismissed James Howells&#8217; legal claim to recover the hard drive, citing no &#8220;reasonable grounds&#8221; for bringing the claim and &#8220;no realistic prospect&#8221; of winning it.
Howells, who had sued the Newport City Council in Wales over the case, said he was &#8220;very upset&#8221; after the ruling, saying &#8220;it&#8217;s the great British injustice system striking again.&#8221;
After trying for 12 years to recover the lost coins, the ruling felt like &#8220;a kick in the teeth,&#8221; Howells lamented.
The case stems from an incident in 2013 when Howells accidentally threw away a hard drive containing 8,000 BTC.
The hard drive was discarded in a landfill in Newport, Wales, and Howells sought permission from Newport Council to <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41308908/man-who-accidentally-threw-hard-drive-containing-8-000-bitcoins-worth-half-a-billion-dolla">excavate the site</a> in order to recover it.
However, the council rejected his request, and the court ruled that the council&#8217;s environmental permits prohibit excavation.
James Goudie KC, representing the council, argued that once the hard drive entered the landfill, it became the council's property.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42881109/bitcoin-is-suffering-from-a-shift-in-macro-expectations-analyst-says-heres-what-that-means">Bitcoin Is Suffering From A Shift In Macro Expectations, Analyst Says: Here&#8217;s What That Means</a>
Why It Matters: At the current market price of $93,128.86, the 8,000 Bitcoins on the discarded hard drive are worth about $745.03 million. 
This is a significant decrease compared to mid-December 2024, when Bitcoin's value peaked at $108,268.45.
Howells had repeatedly requested permission from the council to access the landfill site, offering a share of the Bitcoin in exchange for its recovery. 
Despite his persistent efforts, the court&#8217;s ruling has put an end to his claims.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42900509/social-media-sentiment-report-shows-only-one-out-of-bitcoin-xrp-dogecoin-is-bullish">Social Media Sentiment Report Shows Only One Out Of Bitcoin, XRP, Dogecoin Is Bullish</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Man Who Accidentally Threw Away 8,000 Bitcoin Hard Drive Suffers New 'Kick In The Teeth' As UK Court Dismisses His Claim

Fifth Third Bancorp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NYSE">FITB</a>) short percent of float has fallen 4.65% since its last report. The company recently reported that it has 18.81 million shares sold short, which is 3.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Fifth Third Bancorp Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fifth Third Bancorp has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Fifth Third Bancorp's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Fifth Third Bancorp's peer group average for short interest as a percentage of float is 0.96%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FITB

Looking Into Fifth Third Bancorp's Recent Short Interest

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has risen 151.76% since its last report. The company recently reported that it has 4.00 million shares sold short, which is 2.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 4.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TNXP

(TNXP) - Analyzing Tonix Pharmaceuticals's Short Interest

JPMorgan Chase's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) short percent of float has fallen 4.59% since its last report. The company recently reported that it has 29.19 million shares sold short, which is 1.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>JPMorgan Chase Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451012_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for JPMorgan Chase has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing JPMorgan Chase's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, JPMorgan Chase's peer group average for short interest as a percentage of float is 1.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(JPM) - Analyzing JPMorgan Chase's Short Interest

In the current market session, Select Medical Hldgs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) share price is at $18.73, after a 0.48% increase. Moreover, over the past month, the stock decreased by 5.59%, but in the past year, spiked by 31.69%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1736450112_0.png" alt="Past Year Chart" />

<h3>Select Medical Hldgs P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 25.68 in the Health Care Providers &amp; Services industry, Select Medical Hldgs Inc. has a lower P/E ratio of 8.75. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1736450112_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Select Medical Hldgs

<a href="https://www.ft.com/content/38c519c3-1fe9-4d2c-9d8c-6dd158ab35aa" title="https://www.ft.com/content/38c519c3-1fe9-4d2c-9d8c-6dd158ab35aa">https://www.ft.com/content/38c519c3-1fe9-4d2c-9d8c-6dd158ab35aa</a>

Politics

General

OKLO

Report From Jan. 3 "US relaxes green hydrogen rules in race to boost sector" -Financial Times

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">investor outlook for 2025</a>.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector&#8217;s performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500&#8217;s 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Ahead of the 2025 JPM Healthcare Conference, JP Morgan highlights some investor expectations as sentiment remains mixed for the US Large Cap BioPharma group heading into 2025. The conference is scheduled between 13 January and 16 January.
Obesity is expected to remain a major focus for the industry. The sector&#8217;s focus on the below advancements highlights the growing importance of obesity treatments and related drug innovations:
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): Increased emphasis on incretin therapies as production capacity grows and direct-to-consumer advertising gains traction. Key data catalysts: Phase 3 results for orforglipron, an oral <a href="https://www.benzinga.com/general/biotech/23/07/33339766/ozempic-alternatives-these-two-drugs-show-promise-in-affordability-and-effectiveness-for-weight-l" target="_blank" rel="noreferrer noopener">small molecule GLP-1</a>.</li>
<li>Initial outcomes data for tirzepatide <a href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" target="_blank" rel="noreferrer noopener">in type 2 diabetes</a>.</li>
</ul>
Several new product launches are on the radar for 2025. Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stands out as a top pick, with the anticipated launch of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">Cobenfy for schizophrenia</a>.
JP Morgan analyst Chris Schott expects a strong adoption once broader insurance coverage, expected by the second half of 2025, is in place.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is also preparing for a mid-2025 launch of lenacapavir for pre-exposure prophylaxis, with promising uptake <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">projected into 2026</a>.
Additionally, JP Morgan is monitoring Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair for pulmonary arterial hypertension, which has already <a target="_blank" href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" rel="noreferrer noopener">exceeded early expectations</a>, and Gilead&#8217;s Livdelzi for primary biliary cholangitis, expected to see more significant growth in 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016935/gilead-unveils-long-term-data-from-seladelpar-in-patients-with-rare-liver-disease" rel="noreferrer noopener">as access improves</a>.
The analyst is watching for updates on how companies are approaching business development after a relatively quiet 2024. While major changes are not anticipated in the size or type of deals pursued by large-cap companies, JP Morgan expects M&amp;A activity to pick up in 2025.
Large deals over $25 billion remain unlikely, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" target="_blank" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a></li>
</ul>
Image via Shutterstock

Biotech

AMGN

GILD

REGN

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares are trading higher by some 7% to $118.23 over the trailing week. JPMorgan analyst Harlan Sur this week <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42859614/jpmorgan-sees-marvells-ai-revenue-surge-with-2-billion-run-rate-in-networking-by-2025">provided an optimistic outlook</a> for the company, highlighting the company's strong momentum in AI-driven growth.
Marvell also unveiled its <a href="https://www.benzinga.com/news/25/01/42820909/whats-going-on-with-marvell-technology-mrvl-stock">custom XPU architecture</a>, integrating co-packaged optics to enhance AI server scalability with superior data transmission reach and energy efficiency.
What To Know: Sur <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42859614/jpmorgan-sees-marvells-ai-revenue-surge-with-2-billion-run-rate-in-networking-by-2025">highlighted</a> that Marvell is set to surpass its $2.5 billion AI revenue target for CY25, fueled by robust demand for optical and copper networking products and AI ASIC programs with Amazon and Google.
Read Also: <a href="https://www.benzinga.com/25/01/42899028/la-wildfire-damages-estimated-above-52-billion-california-property-insurance-crisis">LA Wildfire Damages Could Top $52 Billion As California Faces Property Insurance Crisis</a>
The company is also expanding into scale-up networking with advanced solutions like active electrical cables, co-packaged optics and linear pluggable optics.
Sur noted Marvell's partnership with Amazon remained solid, with expectations of sustained multi-generational product wins. Despite competition from Amazon's 3nm AI compute ASIC program, Marvell anticipated no revenue disruptions through CY26, projecting continued growth.
Sur also described the company's $8 billion AI Custom ASIC revenue target for CY28 as conservative given the market's rapid expansion.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/01/42895251/mrvl-stock-has-gained-over-7-in-last-five-sessions-as-marvell-technologys-new-chip-boosts-ai-server-performance-heres-what-technical-analysis-says">MRVL Stock Has Gained Over 7% In Last Five Sessions As Marvell Technology&#8217;s New Chip Boosts AI Server Performance: Here&#8217;s What Technical Analysis Says</a>
<h1 class="wp-block-heading">Is MRVL A Good Stock To Buy?</h1>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages — such as <a href="https://www.benzinga.com/quote/MRVL">Marvell</a>&#8216;s page for example — there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Marvell Tech does pay a dividend, which yields 0.31% per year as of the closing price on Jan. 9, 2025. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 18.34%, you'll need to buy a share of Orchid Island Cap by Jan. 31, 2025. Once done, you can expect to receive a nominal payout of $0.12 on Feb. 12, 2025.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/MRVL">Marvell</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MRVL has a 52-week high of $126.12 and a 52-week low of $53.19.
Image courtesy of <a href="http://Pixabay">Pixabay</a>

MRVL

What's Going On With Marvell Technology (MRVL) Stock?

Election Promises Meet Reality

COP29: Temperature Overshoot, Policy Undershoot

Opportunity In Uncertain Times: Strategies For Long-Term Investors

Clean Energy Industry Braces For The Trump Economy Redux

COP29: Show Me The Money!

The Energy Transition: Fueling Tomorrow's Economy

2025 Global Outlook - Building The Transformation

Operating Expenses Grow By Over $73B For U.S. Investment-Grade Companies In Q3

Q1 2025 Equity Market Outlook

5 Things To Watch In Energy Markets In 2025

ACES

ACTV

AFMC

AFSM

AGNG

AIBU

ANEW

ARKG

ARKK

ARKQ

ARTY

ASHR

ASHS

AVUV

BAPR

BMED

BMVP

BOIL

BOTZ

CBON

CCSO

CHIQ

CNCR

CNXT

CNYA

CQQQ

CRBN

CTEC

CXSE

DEUS

DRAG

DRIV

DTCR

DTEC

EATV

ECLN

ECNS

EDOC

EFRA

EMCR

EQAL

ERTH

ETHO

FCOM

FDIS

FEDM

FEIG

Comments

ProShares S&P Kensho Cleantech ETF

뉴스

에 대한 최신 뉴스 ProShares S&P Kensho Cleantech ETF (ARCA:CTEX)

화요일, 1월 07, 2025

뉴스

파트너 / 기고자

벤징가 글로벌